127 related articles for article (PubMed ID: 12829606)
1. B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs.
Kamio T; Toki T; Kanezaki R; Sasaki S; Tandai S; Terui K; Ikebe D; Igarashi K; Ito E
Blood; 2003 Nov; 102(9):3317-22. PubMed ID: 12829606
[TBL] [Abstract][Full Text] [Related]
2. Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Ono A; Kono K; Ikebe D; Muto A; Sun J; Kobayashi M; Ueda K; Melo JV; Igarashi K; Tashiro S
Genes Chromosomes Cancer; 2007 Jan; 46(1):67-74. PubMed ID: 17044046
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
Vieira SA; Deininger MW; Sorour A; Sinclair P; Foroni L; Goldman JM; Melo JV
Genes Chromosomes Cancer; 2001 Dec; 32(4):353-63. PubMed ID: 11746976
[TBL] [Abstract][Full Text] [Related]
4. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
6. Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies.
Muto A; Tashiro S; Tsuchiya H; Kume A; Kanno M; Ito E; Yamamoto M; Igarashi K
J Biol Chem; 2002 Jun; 277(23):20724-33. PubMed ID: 11923289
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
[TBL] [Abstract][Full Text] [Related]
8. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
10. Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15.
Sasaki S; Ito E; Toki T; Maekawa T; Kanezaki R; Umenai T; Muto A; Nagai H; Kinoshita T; Yamamoto M; Inazawa J; Taketo MM; Nakahata T; Igarashi K; Yokoyama M
Oncogene; 2000 Aug; 19(33):3739-49. PubMed ID: 10949928
[TBL] [Abstract][Full Text] [Related]
11. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
12. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
[TBL] [Abstract][Full Text] [Related]
13. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.
Yoshida C; Yoshida F; Sears DE; Hart SM; Ikebe D; Muto A; Basu S; Igarashi K; Melo JV
Blood; 2007 Feb; 109(3):1211-9. PubMed ID: 17018862
[TBL] [Abstract][Full Text] [Related]
14. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress abolishes leptomycin B-sensitive nuclear export of transcription repressor Bach2 that counteracts activation of Maf recognition element.
Hoshino H; Kobayashi A; Yoshida M; Kudo N; Oyake T; Motohashi H; Hayashi N; Yamamoto M; Igarashi K
J Biol Chem; 2000 May; 275(20):15370-6. PubMed ID: 10809773
[TBL] [Abstract][Full Text] [Related]
16. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.
Legros L; Bourcier C; Jacquel A; Mahon FX; Cassuto JP; Auberger P; Pagès G
Blood; 2004 Jul; 104(2):495-501. PubMed ID: 14976047
[TBL] [Abstract][Full Text] [Related]
20. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
